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Background: Management of erosive Oral Lichen Planus (eOLP) is challenging. Currently, topical corticosteroids 
are widely used as first-line therapy, but they might be associated with side-effects and incomplete clinical re-
sponse. Among non-pharmacological strategies, ozone at low medical concentration has proven to induce a mild 
activation of protective anti-oxidant pathways, thus exerting therapeutic effects in many inflammatory diseases. 
The aim of this randomized controlled study was to investigate the effectiveness of ozonized water in association 
with conventional topical corticosteroids for the treatment of eOLP.
Material and Methods: Fifty-one patients were included in the study and randomized into 2 groups: study group 
(n=26) included patients receiving ozonized water treatment; control group (n=25) included patients receiving 
placebo treatment (i.e. double-distilled water). Treatment protocol consisted of 1-minute oral rinses, repeated for 
4 times, twice a week for 4 weeks. All patients received conventional corticosteroid topical therapy (betametha-
sone soluble tablets, 2 rinses/day for 4 weeks). Assessment of size of lesions, sign and pain scores was performed 
before treatment, after 2 weeks of treatment (T1) and at the end of 4-week treatment (T2). Efficacy Index (EI) of 
treatment, candidiasis and relapse rates were also recorded.
Results: All patients experienced significant improvement of sign and pain scores with a higher rate of improve-
ment in ozone-treated group (T1 improvement rates: Thongprasom 92.2% vs 28%; VAS pain 76.9% vs 32%; 
p<0.05). Pain and size reduction were significantly higher in ozone-treated group both at T1 and T2 (p<0.05). 
Ozone-treated group showed a higher EI at every time point (T0-T2: 72.77% vs 37.66%, p<0.01). Candidiasis 
(32% vs 11.5%) and relapse (40% vs 34.6%) rates were higher in control group, however the differences were not 
statistically significant.
Conclusions: Within the limitations of this study, ozonized water seems to be effective as an adjunct therapy, in 
combination with topical corticosteroids, for the treatment of eOLP.
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Introduction
Oral Lichen Planus (OLP) is a chronic inflammatory dis-
order of the oral mucosa of unknown etiology, affecting 
approximately 2% of the population (1). It is considered 
a middle age disease (30-60 years of age) with a female 
to male ratio being 2:1 (2). The pathogenic mechanism 
consists of apoptosis of basal keratinocytes induced 
by CD8+ T cells because of an underlying immune 
disorder. Typically, the disease presents with multiple 
lesions, mostly with bilateral and symmetric distribu-
tion. Andreasen’s classification distinguishes 6 clinical 
presentations of OLP including reticular, plaque-like, 
atrophic (erythematous), erosive-ulcerous and bullous-
erosive (3). Reticular, papular and plaque-like forms are 
the most common and usually painless; they are similar 
to other white disorders such as leukoplakia, appearing 
as white hyperkeratotic striae or plaques (4). Erosive 
and atrophic forms, on the contrary, are often associ-
ated with discomfort, pain and intolerance to spicy and 
hot food assumption. In addition, erosive long-lasting 
OLP is associated with a significant potential for ma-
lignant transformation with an estimated risk of 0.5-2% 
(2). Therefore, treatment of these forms and long-term 
monitoring are essential. Clinical management of ero-
sive OLP (eOLP) is challenging, with no definitive cure 
available. Treatment aims primarily at abolishing the 
symptoms and at extending the duration of remission 
periods, but complete eradication of the disease is cur-
rently not achievable (5). A variety of treatments have 
been suggested, but there is no strong evidence for the 
effectiveness of any of them. Treatments include topical 
and systemic corticosteroids, topical calcineurin inhibi-
tors, retinoids, immunosuppressants and anti-inflam-
matory coating gels (5). Currently, topical and systemic 
corticosteroids are widely used as first-line therapy, but 
they might be associated with side-effects, incomplete 
clinical response and frequent relapses (6). In particu-
lar, topical corticosteroids are considered the gold stan-
dard therapy for OLP, whereas systemic therapy is re-
served only for multi-organ involvement or for severe 
cases resistant to conventional treatment (7). Neverthe-
less, long-term treatment with topical corticosteroids 
may be associated to adverse effects such as dysgeusia, 
tachyphylaxis, oral mucosa thinning, systemic absorp-
tion and secondary candidiasis (7,8).
The evaluation of other therapeutic strategies and non-
pharmacological approaches is therefore essential. Pho-
tobiomodulation therapy (PBMT), previously known as 
low-level laser therapy (LLLT), has been widely used 
as a non-pharmacological alternative to corticosteroid 
therapy and it has proven effective, without any remark-
able adverse effect (9,10). However, further studies with 
strict inclusion criteria, randomization, larger samples 
and precise standardization of the laser type and set-
ting are required in order to evaluate long-term safety 
and efficacy (11). Among non-pharmacological strate-
gies, the use of ozone (O3) as a complementary medical 
approach has progressively been increasing. Ozone is a 
highly unstable atmospheric gas that rapidly decays into 
normal oxygen (O2). Although not being a radical mol-
ecule, O3 is a very strong oxidant and, due to this highly 
toxic property, it has been widely used as a disinfectant 
and germicidal agent, also for medical purposes (12). 
In addition, O3 administration as O2-O3 gas mixture 
has proven to improve metabolic activity and to exert 
therapeutic effects in numerous diseases (13).
Many T-cell mediated inflammatory diseases are driv-
en by underlying imbalances in antioxidant response 
(14,15). Ozone at low medical concentrations induces 
a mild activation of protective anti-oxidant pathways, 
such as nuclear factor erythroid – related 2 (Nrf2) path-
way, that help restore a redox homeostasis. (15) Nrf2 
is able to modulate inflammation through the down-
regulation of pro-inflammatory cytokines synthesis, 
reactive oxygen species (ROS) levels and transcrip-
tional activity of nuclear factor kappa-B (NF-kB). The 
modulation of ROS levels by Nrf2 pathway is crucial in 
maintaining a proper T-cell mediated immunity (15,16). 
As a result, increased Nrf2 expression limits T cell acti-
vation and controls the differentiation of inflammatory 
T cell subsets, skewing the immune response towards 
more anti-inflammatory phenotypes (14,17). Unfortu-
nately, the application of ozone therapy is still limited 
due to the numerous doubts about its possible toxicity 
(18). However, recent studies have helped to clarify that 
exposure to low O3 concentrations stimulates cell pro-
tective pathways and nuclear transcription without in-
ducing cell damage and altering cell proliferation and 
survival (18,19). Given its therapeutic mechanisms, we 
hypothesize that ozone therapy can decrease the sever-
ity of eOLP symptoms, manage the risk of candidiasis 
superinfection and induce a faster healing of the le-
sions. Ozonized water was the chosen formulation as 
it overcomes the issues of gaseous ozone, including gas 
dispersion, potentially associated with risk of inhalation 
toxicity and reduction of local effectiveness.
The aim of this study was to investigate the use of ozon-
ized water for the treatment of eOLP, in association 
with conventional topical corticosteroids application, in 
terms of efficacy index, clinical scores (i.e. VAS pain, 
size of lesions and Thongprasom scores) and candidia-
sis infection and relapse rates. To the best of our knowl-
edge there are no similar studies.
Material and Methods
- Sample selection
This study was carried out at the Dental Clinic of the 
University of Brescia, Brescia - Italy January 2018 to 
December 2019, including a 3-month follow-up. Fifty-
five consecutive patients with eOLP were enrolled.
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Inclusion criteria were: (a) histopathological diagnosis 
of OLP, according to the conventional WHO criteria  (b) 
clinical erosive form, according to the clinical criteria of 
van der Meij and van der Waal  (c) symptomatic lesions 
(20). Exclusion criteria were: (a) lesions showing OLP 
and dysplasia (b) lesions showing OLP and candidia-
sis (c) oral lichenoid lesions (d) patients who underwent 
corticosteroids or other immunosuppressive treatment. 
Data concerning age, sex and general medical history 
were collected.
- Study design
This study was designed as a randomized placebo-
controlled study. Patients were randomized by com-
puter code into two groups. Group A included patients 
receiving ozonized water treatment (Aquolab Profes-
sional, Sweden & Martina S.p.A, Padova, Italy) i.e. 
1-minute oral rinses (double-distilled water to ozone 
ratio being 2:3), repeated for 4 times, twice a week for 
4 consecutive weeks, for a total of 8 applications; group 
B included patients receiving placebo treatment, i.e. of 
double-distilled water oral rinses, with the same dura-
tion and timing. Water ozonization was carried out at 
each appointment, 5 minutes before application.
All patients received conventional corticosteroid topi-
cal therapy (betamethasone sodium phosphate 500 mg 
soluble tablets, 2 rinses par day for 4 weeks).
Patients were evaluated before the treatment (T0), after 
2 weeks (T1), at the end of the treatment (T2) and after 
3 months as a follow-up (T3).
OLP clinical course was assessed by measuring sever-
ity of pain, lesions size, clinical signs and efficacy of the 
treatment. Clinicians who evaluated the outcomes were 
blinded to the allocation group.
- Pain scoring
The severity of pain was determined using a vi-
sual analogue scale (VAS) from 0 to 10 where 0 cor-
responds to “no pain” and 10 to “the worst possible 
pain”. The symptoms data were then scored accord-
ing to the following classification: score 3: severe 
pain/discomfort (7<VAS<10); score 2: moderate pain/
discomfort (3.5<VAS<7); score 1: mild pain/discom-
fort (0<VAS<3.5); score 0: without pain/discomfort 
(VAS=0) (21).
- Clinical signs and size of lesions
The lesion size was defined as the main diameter (mm) 
of the worst atrophic and erosive lesion of OLP, mea-
sured with a periodontal probe. The scoring was per-
formed by two calibrated clinicians.
The change in clinical signs was assessed through 
Thongprasom sign scoring system as follows: score 5: 
white striae with erosive area >1 cm2; score 4: white 
striae with erosive area <1 cm2; score 3: white striae 
with atrophic area >1 cm2; score 2: white striae with 
atrophic area <1 cm2; score 1: white striae only; score 
0: no lesions, normal mucosa (22).
- Efficacy of the treatment
Treatment efficacy index (EI) was calculated, using the 
following formula:
[(Total score of the lesion before treatment – Total score 
of the lesion after treatment) / Total score of the lesion 
before treatment] X100
The EI was categorized into 5 rank scale as fol-
lows: healed: 4: EI=100%; marked improvement: 
3: 75%≤EI<100%; moderate improvement: 2: 
25%≤EI<75%; mild improvement: 1: 0<EI<25%; no im-
provement: 0: EI=0 (5).
VAS and Thongprasom improvement were defined as 
transition to a lower VAS score and Thongprasom score 
class, respectively.
Possible candidiasis infection, diagnosed upon clinical 
signs and symptoms along with the presence of candida 
organisms by exfoliative cytology, was also recorded 
during treatment.
Relapse rate was also recorded 3 months after the end 
of the treatment (T3) and it was defined as worsening of 
at least one between VAS score or Thongprasom signs 
score.
- Statistical analysis
All data were recorded in Microsoft Excel datasheets 
and statistical analysis was performed using IBM SPSS 
Statistics (v25, Inc, Chicago, IL, USA). Descriptive 
analysis was carried out and data were presented as fre-
quency, percentage, mean, standard deviation, median, 
interquartile range. The Kolmogorov-Smirnov test was 
used to assess data distribution. As data did not exhibit 
normal distribution, non-parametric tests were chosen. 
U-Mann-Whitney test was used to evaluate any differ-
ence in pain and clinical scores between groups and 
Wilcoxon matched paired test was used to determine 
any difference at different time points. Percentages of 
EI values, improvement, relapse and candidiasis rates 
were compared using Chi-square or Fisher’s exact test. 
Estimating a moderate improving (E.I. ≥ 2) at the end of 
the treatment in 90% of the cases for the ozone-treated 
group and in 55% for the control group, the minimum 
number of patients for the study, assuming alpha 0.05 
and beta 0.20 (study power = 80 %), was calculated to 
be 50 (at least 25 per group) (9).
Results
Fifty-five patients affected by atrophic-erosive OLP 
were recruited for the study according to inclusion 
criteria. Four patients were lost to T2 scheduled ap-
pointments and follow-up and were excluded from the 
study. Therefore, a total of 51 patients (35 females and 
16 males) were included. The mean age of the patients 
was 65.14 (range 46-83). The oral sites involved were 
buccal mucosa, gums and dorsum of the tongue. Initial 
demographic and clinical features were similar for both 
groups (p>0.05) (Table 1). 
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Reduction in signs and pain scores at different time 
points throughout the study, within the same group, was 
statistically significant. (Wilcoxon paired test, p<0.001).
With regards to pain evaluation, VAS clinical features 
are displayed in Table 2. Pain reduction was significant-
ly higher in group A both at T1 and T2 (p<0.05). (Fig. 
1) Most of the patients reported a VAS score of 2 (mod-
erate pain) at T0, which lowered to score 1 or 0 at T2. 
VAS score difference between groups was statistically 
significant both at T1 and T2 (p<0.05).
All patients experienced a significant improvement of 
symptoms throughout the treatment, however, both at 
T1 and T2 a higher rate of improvement was found in 
group A, with a statistically significant difference at T1 
(p=0.001).
Size of the lesions ranged from 2 to 20 mm. Size fea-
tures and Thongprasom signs scores are displayed in 
Table 3. The difference in reduction of lesions size be-
tween groups was statistically significant at T1 (p<0.05) 
and T2 (p=0.001). (Fig. 2) Most patients showed Thong-
GROUP A (n=26) GROUP B (n=25) p-value Total (n=51)
Male-Female 8:18 8:17 0.581 16:35
Age (mean/range) 65.73 (47-83) 64.52 (46-81) 0.672 65.14 (46-83)
1Exact Fisher’ test, 2T-Student test; *Significant value p<0.05
Table 1: Demographic characteristics of the patients.
GROUP A GROUP B p-value1 Total
VAS
median (IQR)
T0 5 (3) 4 (4) 0.199 4 (3)
T1 2 (2) 3 (4) 0.018* 3 (2)
T2 0.5 (1) 1 (3) 0.040* 1 (2)
GROUP A GROUP B p-value1 Total
VAS SCORE
median (IQR)
T0 2 (1) 2 (1) 268 2 (1)
T1 1 (0) 1 (1) 0.011* 1 (0)
T2 0.5 (1) 1 (1) 0.014* 1 (1)
GROUP A GROUP B Total
VAS SCORE 
DISTRIBUTION
number of cases (%)
T0 0 0 (0.0%) 0 (0.0%) 0 (0.0%)
1 8 (30.8%) 11 (44.0%) 19 (37.3%)
2 17 (65.4%) 14 (56.0%) 31 (60.8%)
3 1 (3.8%) 0 (0.0%) 1 (2%)
T1 0 3 (11.5%) 2 (8.0%) 5 (9.8%)
1 23 (88.5%) 15 (60.0%) 38 (74.5%)
2 0 (0.0%) 8 (32.0%) 8 (15.7%)
3 0 (0.0%) 0 (0.0%) 0 (0.0%)
T2 0 13 (50.0%) 6 (24.0%) 19 (37.3%)
1 13 (50.0%) 14 (56.0%) 27 (52.9%)
2 0 (0.0%) 5 (20.0%) 5 (9.8%)
3 0 (0.0%) 0 (0.0%) 0 (0.0%)
GROUP A GROUP B p-value2 Total
VAS IMPROVE
number of cases (%)
T1 Yes 20 (76.9%) 8 (32.0%)
0.001*
28 (54.9%)
No 6 (23.1%) 17 (68.0%) 23 (45.1%)
T2 Yes 10 (38.5%) 7 (28.0%)
0.311
17 (33.3%)
No 16 (61.5%) 18 (72.0%) 34 (66.7%)
IQR: interquartile range; 1 U Mann-Whitney test, 2 Fisher’s exact test; *Significant value: p<0.05. 
Table 2: VAS pain distribution at T0, T1, T2.
Fig. 1: VAS pain median values over time.
prasom score 2 and 4 at T0, which averagely improved 
to grade 1 after treatment (T2). Thongprasom signs 
score improvement rate was higher in group A, but a 
statistically significant difference was found only at T1 
(p<0.001) (Fig. 3).
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Efficacy Index (EI) data, relapse and candidiasis rates 
are shown in Table 4. Most of the patients showed a 
moderate improvement (EI=2) at the end of the treat-
ment in both groups. EI of the treatment was signifi-
cantly higher for group A (p<0.05) at every time point.
Relapse rate at T3 was higher in group B (40%) com-
pared to group A (34.6%), however the difference was 
not statistically significant (p=0.457).
The rate of candidiasis infection during treatment was 
not significantly different (p=0.075) between groups, 
however a higher number of patients was affected in 
group B (n=8) if compared to group A (n=3).
GROUP A GROUP B p-value1 Total
Lesion diameters 
mm - median (IQR)
T0 7 (5) 7 (6) 0.842 7 (6)
T1 4 (4) 6 (5) 0.024* 5 (4)
T2 1.5 (2) 3 (7) 0.001* 2 (3)
GROUP A GROUP B p-value1 Total
Thongprasom score 
median (IQR)
T0 3 (2) 4 (2) 0.693 3 (2)
T1 2 (1) 2 (2) <0.001* 2 (2)
T2 1 (1) 2 (2) <0.001* 1 (1)
GROUP A GROUP B Total
Thongprasom score 
distribution
number of cases (%)
T0
0 0 (0.0%) 0 (0.0%) 0 (0.0%)
1 0 (0.0%) 0 (0.0%) 0 (0.0%)
2 10 (38.5%) 9 (36.0%) 19 (37.3%)
3 4 (15.4%) 3 (12%) 7 (13.7%)
4 8 (30.8%) 8 (32.0%) 16 (31.4%)
5 4 (15.4%) 5 (20.0%) 9 (17.6%)
T1
0 0 (0.0%) 0 (0.0%) 0 (0.0%)
1 11 (42.3%) 0 (0.0%) 11 (21.6%)
2 11 (42.3%) 13 (52.0%) 24 (47.1%)
3 0 (0.0%) 3 (12%) 3 (5.9%)
4 4 (15.4%) 7 (28.0%) 11 (21.6%)
5 0 (0.0%) 2 (8.0%) 2 (3.9%)
T2
0 8 (30.8%) 2 (8.0%) 10 (19.6%)
1 15 (57.7%) 6 (24.0%) 21 (41.2%)
2 3 (11.5%) 11 (44.0%) 14 (27.5%)
3 0 (0.0%) 3 (12%) 3 (5.9%)
4 0 (0.0%) 3 (12%) 3 (5.9%)
5 0 (0.0%) 0 (0.0%) 0 (0.0%)
GROUP A GROUP B p-value2 Total
Thongprasom im-
prove
number of cases (%)
T1 Yes 25 (92.2%) 7 (28.0%) <0.001* 32 (62.7%)No 1 (3.8%) 18 (72.0%) 19 (37.3%)
T2 Yes 19 (73.1%) 16 (64.0%) 0.346 35 (68.6%)No 7 (26.9%) 9 (36.0%) 16 (31.4%)
IQR: interquartile range; 1 U Mann-Whitney test, 2 Fisher’s exact test; *Significant value: p<0.05
Table 3: Lesion size and signs score (Thongprasom score) at T0, T1, T2.
Fig. 2: Size of lesions (median, mm) over time.
Fig. 3: Clinical presentation of emblematic cases from study group 
(a; b) and from control group (c; d), before (a; c) and after treatment 
(b; d) respectively. (Study group: betamethasone rinses associated 
with ozonized water rinses. Control group: betamethasone rinses 
and placebo (double-distilled water) rinses).
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Discussion
OLP is a common chronic immunological disease and 
its management is still challenging for clinicians. Cur-
rently there are no resolutive treatments available and 
the main aim of therapy is to relieve inflammation, pain 
and discomfort associated with the erosive forms of the 
disease. In addition, long lasting atrophic-erosive OLP 
are associated with a significantly higher potential for 
malignant transformation than reticular-keratotic forms 
(2). Topical corticosteroids are widely accepted as first 
line-therapy for symptomatic OLP. However, prolonged 
use of this group of medication should be avoided, as it 
is associated with many adverse effects such as dysgeu-
sia, systemic absorption, secondary fungal infections 
and increased risk of malignancies because of immune 
system suppression (8). The introduction of alternative 
safe treatment methods is, therefore, strongly required. 
PBMT has long been used for many oral inflammatory 
diseases and its efficacy is widely supported by clini-
cal practice. PBMT seems to induce acceleration of 
wound healing, anti-inflammatory effects, stimulation 
of cellular metabolism, immune-modulation, vasodila-
tation and analgesic effects (23). However, the efficacy 
of PBMT depends on many parameters such as power, 
wavelength, intensity, exposure time, modality of ap-
plication and treatment protocol. Therefore, PBMT effi-
cacy is still controversial and further studies are needed 
(5,11). 
Among non-pharmacological strategies, ozone use has 
been increasing as a complementary medical approach. 
Ozone has many therapeutic properties, including im-
mune-modulation, pain relief, promotion of biosynthetic 
activities, antioxidant, antimicrobial and wound healing 
properties. In addition, it enhances microcirculation in 
tissues (13). Kazancioglu et al. found that, although both 
ozone and laser therapies had a positive effect on bone 
formation in rat calvarial defect, ozone therapy was 
more effective than PBMT (24).  A study by Erdemici 
et al. demonstrated that ozone has beneficial effects on 
wound healing both on hard and soft tissue in an experi-
mental model, as it reduced inflammation and edema 
by activating biochemical mechanisms and antioxidant 
GROUP A GROUP B p-value1 Total
Efficacy Index (EI)
mean %
T0 - T1 44.27 12.91 <0.001* 28.9
T1 - T2 50.26 29.2 0.022* 39.93
T0 - T2 72.77 37.66 <0.001* 55.56
GROUP A GROUP B Total
EI score distribution
number of cases (%)
T0-T1
0 1 (3.8%) 14 (56.0%) 15 (29.4%)
1 0 (0.0%) 6 (24.0%) 6 (11.8%)
2 25 (96.2%) 5 (20.0%) 30 (58.8%)
3 0 (0.0%) 0 (0.0%) 0 (0.0%)
4
T1-T2
0 5 (19.2%) 8 (32.0%) 13 (25.5%)
1 0 (0.0%) 5 (20.0%) 5 (9.8%)
2 15 (57.7%) 11 (44.0%) 26 (51.0%)
3 1 (3.8%) 1 (4.0%) 2 (3.9%)
4 5 (19.2%) 0 (0.0%) 5 (9.8%)
T0-T2
0 0 (0.0%) 4 (16%) 4 (7.8%)
1 0 (0.0%) 5 (20.0%) 5 (9.8%)
2 14 (53.8%) 12 (48.0%) 26 (51.0%)
3 7 (26.9%) 4 (16%) 11 (21.6%)
4 5 (19.2%) 0 (0.0%) 5 (9.8%)
GROUP A GROUP B p-value2 Total
Relapse (T3)
number of cases (%) 9 (34.6%) 10 (40.0%) 0.457 19 (37.3%)
Candidiasis
number of cases (%) 3 (11.5%) 8 (32.0%) 0.075 11 (21.6%)
Efficacy Index (EI): 0: no improvement; 1: mild improvement; 2: moderate improvement; 3: marked improvement; 4: healed.
1 U Mann-Whitney test, 2 Fisher’s exact test; *Significant value: p<0.05.
Table 4: Efficacy Index (EI), relapse rate and candidiasis rate distribution.
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systems (25). In the present study we obtained prom-
ising results in terms of reduction of signs and symp-
toms associated to atrophic-erosive OLP. Lesion size, 
Thongprasom score and pain significantly decreased in 
the group treated with ozone and topical corticosteroids 
in comparison to the group treated with corticosteroids 
alone. Our results are consistent with Mostafa et al. who 
found that gaseous ozone treatment in combination with 
topical corticosteroids was more effective than cortico-
steroids alone in reducing sign score and pain of OLP 
throughout the treatment (26). Bayer et al. found that 
both PBMT and gaseous ozone treatment have positive 
effects in the treatment of chemo-radiotherapy induced 
oral mucositis, being PBMT more effective than ozone. 
These results may be related to the duration and dose of 
the laser and ozone applications. Different laser wave-
lengths and different duration, dose and modality of ap-
plication of ozone may change the results (23). Unlike 
the aforementioned studies, we chose ozonized water 
over gaseous ozone. Gaseous ozone requires a direct 
careful and controlled application. In fact, possible gas 
dispersion might be associated to toxicity risk by in-
halation in addition to reduction of local effectiveness. 
Moreover, the mechanism used for gaseous ozone pro-
duction (corona discharge) is associated to relative or 
absolute contraindications (e.g. pregnancy, pacemaker, 
neurological diseases) that must be taken into account. 
Ozonized water rinses might overcome these issues, 
since ozone is produced out of the patient’s mouth and 
immediately conveyed into the medium. Half-life of 
ozone in double-distilled water is approximately 10 
hours. In our protocol, ozonized rinses were performed 
5 to 10 minutes from production in order to maintain 
the original concentration as much as clinically achiev-
able. This formulation allows to reach lesions located up 
to the oropharynx and might be a rapid, safe and easy-
to-use alternative to gaseous ozone and most patients 
showed a high grade of acceptance of the treatment.
The reason for the effectiveness of ozone therapy in 
OLP could be found in the ethiopathogenesis of this 
disease, mediated by CD8+ T lymphocytes. The basal 
layer disruption depends on the cytotoxic effects of 
the T cells in variable distribution at the sub-epithelial 
inflammatory infiltrate. A pivotal role in the pathogen-
esis of this long-lasting inflammatory process is played 
by the activation of nuclear factor kappa B (NF-κB), a 
primary transcription factor which, upon translocation 
to the nucleus, binds to promoter regions of different 
genes encoding immune and proinflammatory media-
tors (16). Ozone therapy induces the modulation of ROS 
levels and transcriptional activity of NF- κB by Nrf2 
pathway and limits T cell activation, inducing more 
anti-inflammatory phenotypes (14,17). The effect of the 
ozone therapy on the activity of CD8+ T cells, that trig-
ger apoptosis of oral epithelial cells in OLP, may explain 
the reduction of the damage on the basal keratinocytes.
Relapse rate resulted lower in the ozone-treated group. 
Though not statistically significant, This outcome might 
suggest that absence of inflammation is maintained fur-
ther in time, since ozone improves the oxygen convey-
ing limit of blood, causing better metabolism of cells 
and tissues and positively affects immune response In 
fact, as Noel at al. previously demonstrated on mouse 
models, T cell–specific activation of Nrf2-regulated an-
tioxidant response appears to help in the maintenance of 
a low proinflammatory environment and optimal T cell 
function that subsequently results in reduced oxidative 
and inflammatory tissue injury (27). A limited 3-month 
follow-up was chosen for the purpose of this study, as 
it is considered to be reasonable both to intercept the 
most recurrent forms of OLP and to limit the other con-
founding factors that may be associated with long-term 
follow-up (28). However, such a short follow-up might 
not fully describe OLP clinical course. Being OLP a 
chronic condition that will most likely recur over time, 
the data reported in this study might underestimate the 
real relapse rate. Therefore, well-designed studies with 
longer follow-ups and experimental models investigat-
ing long-term effects of ozone application are recom-
mended.
Being OLP a disease at risk of malignant transfor-
mation, a consideration about the safety of the ozone 
therapy is due.  Scully et al. identified the basis of the 
malignant transformation of OLP in the accumulation 
in the oral epithelium of the inducible nitric oxide syn-
thase with 8-oxodG (8-nitroguanine and 8-oxo- 7,8- 
dihydro-2¢- deoxyguanosine), which could reflect the 
oxidative and nitrative DNA damage (29). While strong 
oxidative stress fails to properly activate anti-oxidant 
intracellular pathways, mild oxidative stress induces a 
controlled increased expression of anti-oxidant Nrf2. 
The direct and indirect molecular targets of Nrf2 delin-
eate a complex network of biological processes that re-
duce aberrant inflammation, preserve cell homeostasis 
and promote cell reparative programs, thus protecting 
cells from DNA damage, preventing the primary trigger 
of neoplastic transformation and, therefore, supporting 
its safety for the treatment of potentially malignant con-
ditions (14).
Ozone also shows marked antimicrobial activity. In 
fact, in the current study candidiasis rate resulted lower 
in ozone-treated group. This was in line with a study 
conducted by Arita et al. who concluded that the use of 
ozonized water might be useful in reducing the counts 
of oral Candida Albicans on resin denture plates due to 
its strong antifungal properties (30).
Within the limitations of this study, it can be concluded 
that ozonized water rinses can be combined with topi-
cal corticosteroids as an adjunct therapy, resulting safe 
and effective in the treatment of symptomatic eOLP. 
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However, additional studies are recommended, taking 
into account wider samples and long-term follow-ups, 
and, possibly, comparing ozonized water alone versus 
conventional topical corticosteroid treatment. Being 
ozone application relatively new in oral medicine, fur-
ther studies might also be useful to identify the most 
appropriate treatment protocols for inflammatory oral 
diseases.
References
1.  Cheng YS, Gould A, Kurago Z, Fantasia J, Muller S. Diagnosis of 
oral lichen planus: a position paper of the American Academy of Oral 
and Maxillofacial Pathology. Oral Surg Oral Med Oral Pathol Oral 
Radiol. 2016;122:332-54.
2. Bardellini E, Amadori F, Flocchini P, Bonadeo S, Majorana A. 
Clinicopathological features and malignant transformation of oral 
lichen planus:  a 12-years retrospective study. Acta Odontol Scand. 
2013;71:834-40.
3. Andreasen JO. Oral lichen planus. 1. A clinical evaluation of 115 
cases. Oral Surg Oral Med Oral Pathol. 1968;25:31-42.
4. Pinna R, Cocco F, Campus G, Conti G, Milia E, Sardella A, et 
al. Genetic and developmental disorders of the oral mucosa: Epide-
miology; molecular mechanisms; diagnostic criteria; management. 
Periodontol 2000. 2019;80:12-27.
5. Mutafchieva MZ, Draganova-Filipova MN, Zagorchev PI, Tomov 
GT. Effects of Low Level Laser Therapy on Erosive-atrophic Oral 
Lichen Planus. Folia Med (Plovdiv).  2018;60:417-24.
6. Cheng S, Kirtschig G, Cooper S, Thornhill M, Leonardi-Bee J, 
Murphy R. Interventions for erosive lichen planus affecting mucosal 
sites. Cochrane Database Syst Rev. 2012;2:CD008092.
7. Bagan JV, Eisen D, Scully C. The diagnosis and management 
of oral lichen planus: a consensus approach. Oral Biosci Med. 
2004;1:21-7.
8. Lodi G, Carrozzo M, Furness S, Thongprasom K. Interventions 
for treating oral lichen planus: a systematic review. Br J Dermatol. 
2012;166:938-47.
9. Al-Maweri SA, Kalakonda B, Al-Soneidar WA, Al-Shamiri HM, 
Alakhali MS, Alaizari N. Efficacy of low-level laser therapy in man-
agement of symptomatic oral lichen planus: a systematic review. La-
sers Med Sci. 2017;32:1429-37.
10. Amadori F, Bardellini E, Conti G, Pedrini N, Schumacher RF, 
Majorana A. Low-level laser therapy for treatment of chemotherapy-
induced oral mucositis in childhood: a randomized double-blind con-
trolled study. Lasers Med Sci. 2016;31:1231-6.
11. Yang H, Wu Y, Ma H, Jiang L, Zeng X, Dan H, et al. Pos-
sible alternative therapies for oral lichen planus cases refractory 
to steroid therapies. Oral Surg Oral Med Oral Pathol Oral Radiol. 
2016;121:496-509.
12. Travagli V, Zanardi I, Valacchi G, Bocci V. Ozone and ozonated 
oils in skin diseases: a review. Mediators Inflamm. 2010;2010:610418.
13. Elvis AM, Ekta JS. Ozone therapy: A clinical review. J Nat Sci 
Biol Med. 2011;2:66-70.
14. Yarosz EL, Chang CH. The Role of Reactive Oxygen Species in 
Regulating T Cell-mediated Immunity and Disease. Immune Netw. 
2018;18:e14.
15. Galiè M, Covi V, Tabaracci G, Malatesta M. The Role of Nrf2 in 
the Antioxidant Cellular Response to Medical Ozone Exposure. Int J 
Mol Sci. 2019;20:4009.
16. Santoro A, Majorana A, Bardellini E, Festa S, Sapelli P, Facchetti 
F. NF-kB expression in oral and cutaneous lichen planus. J Pathol. 
2003;201:466-72.
17. Sklavos MM, Tse HM, Piganelli JD. Redox modulation inhibits 
CD8 T cell effector function. Free Radic Biol Med. 2008;45:1477-86.
18. Costanzo M, Cisterna B, Vella A, Cestari T, Covi V, Tabaracci G, 
et al. Low ozone concentrations stimulate cytoskeletal organization, 
mitochondrial activity and nuclear transcription. Eur J Histochem. 
2015;59:2515.
19. Scassellati C, Costanzo M, Cisterna B, Nodari A, Galiè M, Catta-
neo A, et al.  Effects of mild ozonisation on gene expression and nu-
clear domains organization in vitro. Toxicol In Vitro. 2017;44:100-10.
20. van der Meij EH, van der Waal I. Lack of clinicopathologic cor-
relation in the diagnosis of oral lichen planus based on the presently 
available diagnostic criteria and suggestions for modifications. J 
Oral Pathol Med. 2003;32:507-12.
21. Gorsky M, Raviv M. Efficacy of etretinate (Tigason) in symptom-
atic oral lichen planus. Oral Surg Oral Med Oral Pathol. 1992;73:52-5.
22. Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. 
Relative efficacy of fluocinolone acetonide compared with triam-
cinolone acetonide in treatment of oral lichen planus. J Oral Pathol 
Med. 1992;21:456-8.
23. Bayer S, Kazancioglu HO, Acar AH, Demirtas N, Kandas NO. 
Comparison of laser and ozone treatments on oral mucositis in an 
experimental model. Lasers Med Sci. 2017;32:673-7.
24. Kazancioglu HO, Ezirganli S, Aydin MS. Effects of laser and 
ozone therapies on bone healing in the calvarial defects. J Craniofac 
Surg. 2013;24:2141-6.
25. Erdemci F, Gunaydin Y, Sencimen M, Bassorgun I, Ozler M, 
Oter S, et al. Histomorphometric evaluation of the effect of systemic 
and topical ozone on alveolar bone healing following tooth extrac-
tion in rats. Int J Oral Maxillofac Surg. 2014;43:777-83.
26. Mostafa B, Zakaria M. Evaluation of Combined Topical Ozone 
and Steroid Therapy in Management of Oral Lichen Planus. Open 
Access Maced J Med Sci. 2018;6:879-84.
27. Noel S, Martina MN, Bandapalle S, Racusen LC, Potteti HR, Ha-
mad AR, et al. T Lymphocyte-Specific Activation of Nrf2 Protects 
from AKI. J Am Soc Nephrol. 2015;26:2989-3000.
28. Sun SL, Liu JJ, Zhong B, Wang JK, Jin X, Xu H, et al. Topical 
calcineurin inhibitors in the treatment of oral lichen planus: a sys-
tematic review and meta-analysis. Br J Dermatol. 2019;181:1166-76.
29.  Scully C, Carrozzo M. Oral mucosal disease: lichen planus. Br J 
Oral Maxillofac Surg. 2008;46:15-21.
30. Arita M, Nagayoshi M, Fukuizumi T, Okinaga T, Masumi S, 
Morikawa M, et al. Microbicidal efficacy of ozonated water against 





The Authors disclose any financial and personal relationships with 
other people or organisations that could inappropriately influence 
their work.
Ethics
All patients were informed about the research and signed an in-
formed consent. The study protocol was approved by the local Ethi-
cal Committee (NP 3814) and it was performed according to the 
Declaration of Helsinki.
